Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP568020.RAACyhFHOv7BtROCYhpIsjmpk9UcXAurdNPT4zR90Aqc4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP568020.RAACyhFHOv7BtROCYhpIsjmpk9UcXAurdNPT4zR90Aqc4130_assertion type Assertion NP568020.RAACyhFHOv7BtROCYhpIsjmpk9UcXAurdNPT4zR90Aqc4130_head.
- NP568020.RAACyhFHOv7BtROCYhpIsjmpk9UcXAurdNPT4zR90Aqc4130_assertion description "[EGFR mutation should be analyzed whenever possible for effective prediction of objective benefit from gefitinib in NSCLC patients with one or more clinical predictors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP568020.RAACyhFHOv7BtROCYhpIsjmpk9UcXAurdNPT4zR90Aqc4130_provenance.
- NP568020.RAACyhFHOv7BtROCYhpIsjmpk9UcXAurdNPT4zR90Aqc4130_assertion evidence source_evidence_literature NP568020.RAACyhFHOv7BtROCYhpIsjmpk9UcXAurdNPT4zR90Aqc4130_provenance.
- NP568020.RAACyhFHOv7BtROCYhpIsjmpk9UcXAurdNPT4zR90Aqc4130_assertion SIO_000772 16956694 NP568020.RAACyhFHOv7BtROCYhpIsjmpk9UcXAurdNPT4zR90Aqc4130_provenance.
- NP568020.RAACyhFHOv7BtROCYhpIsjmpk9UcXAurdNPT4zR90Aqc4130_assertion wasDerivedFrom befree-2016 NP568020.RAACyhFHOv7BtROCYhpIsjmpk9UcXAurdNPT4zR90Aqc4130_provenance.
- NP568020.RAACyhFHOv7BtROCYhpIsjmpk9UcXAurdNPT4zR90Aqc4130_assertion wasGeneratedBy ECO_0000203 NP568020.RAACyhFHOv7BtROCYhpIsjmpk9UcXAurdNPT4zR90Aqc4130_provenance.